NewAmsterdam Pharma Company N.V. (NAMS) Revenue 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$22.5MFY2025 · since FY2022: $102.7M → $22.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $22.5M | -50.6% |
| FY2024 | $45.6M | +223.4% |
| FY2023 | $14.1M | -86.3% |
| FY2022 | $102.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →